Breast‐Conserving Therapy after Neoadjuvant Chemotherapy: Long‐term Results

Abstract:  The purpose of this study was to determine patterns of ipsilateral breast tumor recurrence (IBTR) and local‐regional recurrence (LRR) after neoadjuvant chemotherapy and breast‐conserving therapy (BCT). A total of 153 breast cancer patients were treated with neoadjuvant chemotherapy followed by conservative surgery and radiation therapy between 1980 and 2002. The clinical stage (American Joint Committee on Cancer [AJCC] 1997) at diagnosis was IIA in 22%, IIB in 28%, IIIA in 39%, and IIIB in 11%. The prechemotherapy T size distribution was less than 2 cm in 5 patients, 2.1–5 cm in 100 patients, and greater than 5.1 cm in 48 patients. Sixty‐seven patients (44%) underwent cyclophosphamide, methotrexate, and 5‐fluorouracil (CMF)‐based chemotherapy and 86 (56%) underwent Adriamycin‐based chemotherapy. Thirty‐seven patients (24%) had a complete pathologic response in the breast. All procedures were performed by a single surgeon (G.F.S.). The surgery was local excision alone in 19 patients, local excision and axillary lymph node dissection (ALND) in 130 patients, and ALND alone in 4 patients. Eleven patients had positive surgical margins. Rates of LRR‐, IBTR‐, and distant metastasis (DM)‐free survival were calculated by the Kaplan–Meier method. Patient and pathologic variables were then analyzed in an attempt to identify predictors of clinical outcome. With a median follow‐up period of 55 months (range 6–200 months), eight patients developed LRR, five of which were classified as IBTR. Five‐ and 10‐year actuarial rates of LRR‐free, IBTR‐free, and DM‐free survival were 93% and 88%, 96% and 91%, and 70% and 58%, respectively. Pretreatment and pathologic parameters that positively correlated with IBTR were advanced stage (p = 0.03) and margin positivity (p = 0.04). No other clinical factors were predictive of higher recurrence. BCT results in a low rate of IBTR and LRR in appropriately selected patients. Advanced stage at presentation is associated with increased risk of IBTR, although overall recurrence is low. In selected cases, BCT is safe and an effective alternative to mastectomy. 

[1]  Kelly K. Hunt,et al.  A prospective trial of preoperative chemotherapy in resectable breast cancer: Predictors of breast-conservation therapy feasibility , 2002, Annals of Surgical Oncology.

[2]  S. Singletary,et al.  Predictors of locoregional recurrence among patients with early-stage breast cancer treated with breast-conserving therapy , 2007, Annals of Surgical Oncology.

[3]  P. Okunieff,et al.  Selection of local therapy after neoadjuvant chemotherapy in patients with stage IIIA,B breast cancer , 1998, Annals of Surgical Oncology.

[4]  G. Bonadonna,et al.  Prognostic factors in locally advanced noninflammatory breast cancer. Long-term results following primary chemotherapy , 1990, Breast Cancer Research and Treatment.

[5]  Roman Rouzier,et al.  Breast‐conserving surgery after neoadjuvant anthracycline‐based chemotherapy for large breast tumors , 2004, Cancer.

[6]  G. Hortobagyi,et al.  Proceedings of the Consensus Conference on Neoadjuvant Chemotherapy in Carcinoma of the Breast, April 26–28, 2003, Philadelphia, Pennsylvania , 2004, Cancer.

[7]  G. Hortobagyi,et al.  Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  B. Asselain,et al.  Short and long‐term effects on survival in breast cancer patients treated by primary chemotherapy: an updated analysis of a randomized trial , 1999, Breast Cancer Research and Treatment.

[9]  L. Carey,et al.  Long-Term Outcome of Neoadjuvant Therapy for Locally Advanced Breast Carcinoma: Effective Clinical Downstaging Allows Breast Preservation and Predicts Outstanding Local Control and Survival , 2002, Annals of surgery.

[10]  G. Hortobagyi,et al.  Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  L. Pusztai,et al.  Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma. , 2001, American journal of surgery.

[12]  C. V. D. van de Velde,et al.  Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  A. Vincent-Salomon,et al.  Primary chemotherapy for operable breast cancer: incidence and prognostic significance of ipsilateral breast tumor recurrence after breast-conserving surgery. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  L. Lipton,et al.  Preoperative/neoadjuvant medical therapy for early breast cancer. , 2001, The Lancet. Oncology.

[15]  S J Schnitt,et al.  Outcome at 8 years after breast-conserving surgery and radiation therapy for invasive breast cancer: influence of margin status and systemic therapy on local recurrence. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  G. MacGrogan,et al.  Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonié Bordeaux Groupe Sein (IBBGS). , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  T. Powles,et al.  A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  Anna L. Brown,et al.  Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Wagstaff,et al.  Management of Stage III Breast Cancer , 1998, Oncology.

[20]  D. Wazer,et al.  Factors determining outcome for breast-conserving irradiation with margin-directed dose escalation to the tumor bed. , 1998, International journal of radiation oncology, biology, physics.

[21]  G. Bonadonna,et al.  Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  S. Merajver,et al.  Breast conservation and prolonged chemotherapy for locally advanced breast cancer: the University of Michigan experience. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  D. Wickerham,et al.  Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  E. Touboul,et al.  Primary chemotherapy and preoperative irradiation for patients with stage II larger than 3 cm or locally advanced non-inflammatory breast cancer. , 1997, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[25]  G. Calais,et al.  Conservative treatment feasibility with induction chemotherapy, surgery, and radiotherapy for patients with breast carcinoma larger than 3 cm , 1994, Cancer.

[26]  G. Schwartz,et al.  Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast , 1994, Cancer.

[27]  D. Schultz,et al.  Ten year results of conservative surgery and irradiation for stage I and II breast cancer. , 1991, International journal of radiation oncology, biology, physics.

[28]  G. Fletcher,et al.  Results of mastectomy and postoperative irradiation in the management of locoregionally advanced carcinoma of the breast. , 1991, International journal of radiation oncology, biology, physics.

[29]  A. Luini,et al.  Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. , 1990, Journal of the National Cancer Institute.

[30]  C. Jacquillat,et al.  Results of neoadjuvant chemotherapy and radiation therapy in the breast‐conserving treatment of 250 patients with all stages of infiltrative breast cancer , 1990, Cancer.

[31]  G. Hortobagyi,et al.  Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy , 1988, Cancer.

[32]  A. Korzun,et al.  Combination chemotherapy with mastectomy or radiotherapy for stage III breast carcinoma: a Cancer and Leukemia Group B study. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.